Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism

• DOI: 10.1172/jci.insight.131273
• Publication Date: 2019-11-05T17:01:56Z
• Authors: Huashan Liu; Zhenxing Liang; Fengwei Wang; Chi Zhou; Xiaobin Zheng; Tuo Hu; Xiaowen He; Xianrui Wu; Ping Lan
• Keywords: Proinflammatory cytokine

Conventional treatments for inflammatory bowel disease (IBD) have multiple potential side effects. Therefore, alternative are desperately needed. This work demonstrated that systemic administration of exosomes from human bone marrow–derived mesenchymal stromal cells (MSC-Exos) substantially mitigated colitis in various models IBD. MSC-Exos treatment downregulated responses, maintained intestinal barrier integrity, and polarized M2b macrophages but did not favor fibrosis. Mechanistically, infused acted mainly on colonic macrophages, colitic colons acquired obvious resistance to restimulation when prepared mice treated with versus untreated mice. The beneficial effect was blocked by macrophage depletion. Also, the induction IL-10 production partially involved MSC-Exos. were enriched proteins regulating biological processes associated anticolitic benefit Particularly, metallothionein-2 required suppression responses. Taken together, critical regulators responses may be promising candidates IBD treatment.